期刊文献+

前列腺癌组织Clusterin与p27及Survivin表达临床意义的研究 被引量:3

Clinical significance of the expressions of Clusterin,p27 and Survivin in prostate cancer tissues
原文传递
导出
摘要 目的:探讨凋亡相关蛋白Clusterin、p27和Survivin在前列腺癌组织中的表达及临床意义。方法:应用免疫组织化学方法检测68例前列腺癌组织和47例前列腺增生组织Clusterin、p27和Survivin蛋白的表达。结果:前列腺癌组织Clusterin、p27和Survivin蛋白的阳性表达率分别为75.0%(51/68)、72.1%(49/68)和67.6%(46/68);前列腺增生组织Clusterin、p27和Survivin蛋白的阳性表达率分别为25.5%(12/47)、19.1%(9/47)和23.4%(11/47)。Clusterin、p27和Survivin蛋白阳性表达率在前列腺癌组织和前列腺增生组织中差异有统计学意义,P<0.01。Clusterin、p27和Survivin蛋白表达与前列腺癌病理分级、临床分期和转移情况具有相关性,P<0.05。前列腺癌组织Survivin与Clusterin、Sur-vivin与p27的表达呈正相关,P<0.01。结论:联合检测Clusterin、p27和Survivin蛋白有助于对进展性前列腺癌细胞的侵袭力作出正确评价,以指导临床治疗。 OBJECTIVE:To detect the expressions of Clusterin,p27,Survivin and their correlation in prostate cancer (PCa) tissues. METHODS: Immunohistochemistry was employed to measure the expression of Clusterin, p27 and Survivin in prostatic cancer and 47 cases benign prostatic hyperplasia. RESULTS: In prostatic cancer tissue,the positive expression rates of Clusterin,p27 and Survivin were 75.0% (51/68),72.1 % (49/68) and 67.6% (46/68). In benign prostatic hyperplasia tissue the positive expression rates of Clusterin, p27 and Survivin were 25. 5% (12/47), 19. 1% (9/47), 23.4% (11/47). The positive expression of clusterin,p27 and Survivin between prostatic cancer and benign prostatic hyperplasia were significantly different (P〈0.01). The positive expression of Clusterin, p27 and Survivin were related with the histologic grade, clinical stage and metastasis of prostatic cancer (P〈0.05). The expression of Survivin was a positive correlation with clusterin and p27 expression in prostatic cancer (P〈0.01). CONCLUSION: The detection of Clusterin, p27 and Survivin protein in PCa may help to evaluate the degree of cell apoptosis and decide the therapeutic strategies.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2012年第22期1726-1729,共4页 Chinese Journal of Cancer Prevention and Treatment
关键词 前列腺肿瘤 CLUSTERIN P27 SURVIVIN prostatic neoplasms Clusterin p27 Survivin
  • 相关文献

参考文献14

  • 1Hoffman KE,Chen MH,Moran BJ,et ai. Prostate cancer-specificmortality and the extent of therapy in healthy elderly men withhigh-risk prostate cancer [J]. Cancer,2010,116(11) :2590-2595.
  • 2蒲连美,刘铭,史晓红,魏东,王建业,杨泽.rs6983267和rs1447295与北京地区前列腺癌的关联研究[J].中华肿瘤防治杂志,2012,19(11):804-808. 被引量:1
  • 3Macri A, Versaci A,Lupo G,et al. Role of osteopontin in breastcancer patients[J]. Tumor,2009,95(1) :48-52.
  • 4李欣,汪娜,张彦,张舜欣,林倩,唐杰.端粒酶逆转录酶与血管内皮细胞生长因子在前列腺癌中的表达及其相关性的研究[J].中华男科学杂志,2005,11(10):724-726. 被引量:10
  • 5Trougakos IP, Gonos ES. Clusteri / apolipoprotein J in humanaging and cancer[J]. Int J Bioche Cell Biol, 2002, 34( 11) : 1430-1448.
  • 6Miyake H, Yamanaka K,Muramaki M, et al. Enhanced expres-sion of secreted form of clusterin following neoadjuvant hormonaltherapy as a prognostic predictor in patients undergoing radicalprostatectomy for prostate cancer[J]. Oncol Rep,2005,14 (5):1371-1375.
  • 7Conti M, Moutereau S, Zater M, et al. Urinary cystatin C as aspecific marker of tubular dysfunction[J]. Clin Chem Lab Med,2006,44(3):288-291.
  • 8Ambrosini G, Adida C? Aleteri DC. A novel anti-apoptosis gene,survivin,expressed in cancer and lymphoma[J]. Nat Med,1997,3(8):917-921.
  • 9Jain A, McKnight DA, Fisher LW,et al. Small integrin-bindingproteins as serum markers for prostate cancer detection [J]. ClinCancer Res,2009,15(16) :5199-5207.
  • 10Patil UD, Ragavan A, Nadaraj, et al. Helical CT angiography inevaluation of live kidney donors [J]. Nephrol Dial Transplant,2001,16C9):1900-1904.

二级参考文献30

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1368
  • 2Jemal A, Murray T, Samules A, et al. Cancer Statistics, 2003[J]. CA Cancer J Clin, 2003, 53 ( 1 ) :5-26.
  • 3Counter CM, Avilion AA, LeFeuvre CE, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity[ J ]. EMBO J, 1992,11(5) :1921-1929.
  • 4Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen [ J]. Science,1989, 246(4935 ): 1306-1309.
  • 5Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor ( vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract [ J ].Cancer Res, 1993, 53(19) :4727-4735.
  • 6Boocock CA, Charnock-Jones DS, Sharkey AM, et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma[J]. J Natl Cancer Inst, 1995, 87(7) :506-516.
  • 7Yoshiji H, Gomez DE, Shibuya M, et al. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer [ J]. Cancer Res, 1996, 56 (9):2013-2016.
  • 8Hao XP, Willis JE, Pretlow TG, et al. Loss of fragile histidine traid expression in colorectal carcinomas and premalignant lesions [J]. Cancer Res, 2000, 60(1) :18-21.
  • 9Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human [ J ]. Science, 1997, 277(5328) :955-959.
  • 10Nakayama J, Tahara H, Tahara E, et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas[J]. Nat Genet, 1998, 18(1):65-68.

共引文献9

同被引文献71

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部